Sertoliform Endometrioid Karsinom (SEK) hemen hemen daima postmenapozal hastalarda görülen bir epitelial over tümörü- dür. Bu çal›flmada 67 yafl›nda, sa¤ adneksial alanda 7x6x5 cm’lik kitle ve postmenapozal kanama ön tan›lar› ile bat›n s›v›s› örneklemesi, Total Abdominal Histerektomi ve Bilateralooferektomi uygulanmas› sonucu histolojisi SEK olarak tespit edilen, evresi 1c olan bir hasta sunulmufltur. Yap›lan immunohistokimyasal çal›fl- mada pansitokeratin, epitelial membran antijeni (AMA), ve Ca125 diffüz pozitif, vimentin hücrelerin % 30’unda pozitif, CEA ve S-100 negatif, inhibin az say›da stromal hücre d›fl›nda negatifidi. Adjuvan kemoterapide paklitaksel ve karboplatin kombinasyonu kullan›ld›. Ovaryan Endometrioid Tümörlerin mikroskopik düzeyde çeflitli varyantlar›ndan biri olan SEK gençlerde görülen Sertoli Hücreli Tümörlerden ve Sertoli-Leydig Hücreli Tümörlerden ay›rt edilmelidir. SEK iyi differansiye ve prognozu iyi olan bir tümör olarak kabul edilir. Ayr›c› tan› ve hastal›¤›n yönetimi literatür ›fl›¤›nda tart›fl›lmal›d›r

Sertoliform endometrioid carcinoma (SEC) is an epithelial ovarian neoplasm occuring almost exclusively in post-menopausal patients. In this study a 67-year-old patient who uderwent a total abdominal washing taken for a right ovarian mass measuring 7x6x5 cm and postmenopausal bleeding is presented. Histology revealed an SEC and stage 1c. Immunohistochemical study showed that pancytokeratin, epithelial membrane antigen (EMA) and Ca-125 were positive, vimentine was also positive in 30% of cells and CEA, S-100 were negative and inhibin was negative except some stromal cells. Carboplatin and paclitaxel were used in adjuvant therapy. SEC being the microscopic variant of endometrioid tumours must be distinguished from Sertoli cell tumours and Sertoli-Leydig cell tumours which are encountered at a younger age. SEC is considered a well-diferentiated endometrioid carcinoma with a good prognosis. Differential diagnosis and management of disease discussed in the light of the literatures